Incidence and Management of Driveline Infection in Patients with CH-VAD

NCT ID: NCT06878456

Last Updated: 2025-03-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

181 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-06-01

Study Completion Date

2024-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to learn about the incidence of the Driveline Infection of a novel full-magnetically levitated left ventricular assist device with a new design of driveline.

The main question it aims to answer is : The incidence of DLI in Chinese CH-VAD implanted advanced heart failure patients and the main risk factors.

CH-VAD has been approved in China for the treatment of patients with advanced heart failure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Background: Driveline infection (DLI) is a major complication of left ventricular assist devices (LVADs) and is associated with significant morbidity and mortality. The CH-VAD is a novel, fully magnetically levitated LVAD designed with an ultra-thin and highly flexible driveline, which may reduce the risk of DLI compared to traditional LVADs. Previous research has indicated that driveline design features, such as diameter and flexibility, are key risk factors for DLI. This study aims to assess the incidence, management, outcomes and risk factors of DLI in CH-VAD patients.Rationale: Understanding the incidence and management of DLI in patients receiving the CH-VAD can provide valuable insights into the effectiveness of this device in reducing infection rates. A better understanding of these factors will help refine clinical practices and inform device development to minimize infection risks.
2. Study Design

* Design Type: Retrospective, observational, multicenter study.
* Study Population: 181 consecutive patients who received CH-VAD implantations between June 2017 and October 2024 at 9 centers in China.
* Primary Objective: To evaluate the incidence of DLI in CH-VAD patients.
* Secondary Objectives: To identify factors associated with DLI, assess the management strategies, evaluate patient outcomes, and detect risk factors for DLI.
3. Study Population

• Inclusion Criteria:
* Patients who received CH-VAD implantations for advanced heart failure (AHF) between June 2017 and October 2024.

• Exclusion Criteria:
* No specific exclusion criteria.
4. Data Collection

* Demographic and clinical characteristics from medical records, including age, sex, comorbidities, heart failure etiologies, INTERMACS profiles.
* Surgical details, including device type, duration of support, and concomitant surgeries.
* Infection prevention measures, including the use of prophylactic antibiotics, skin decolonization procedures, driveline fixation sutures, etc.
* Driveline care measures, including dressing change frequency, types of disinfectants, dressing types, fixation measures, etc.
* Incidence and management of DLI, including diagnostic methods, treatment approaches, and outcomes.
* Information on the pathogens involved in DLI and complications such as recurrent infections, driveline revisions, and mortality.
5. Statistical Analysis

* Descriptive statistics will be used to summarize patient demographics, DLI incidence, and outcomes.
* Univariate and multivariate regression analyses will be conducted to identify potential risk factors for DLI.
* Time-to-event analysis will be performed using Kaplan-Meier curves to evaluate freedom from DLI over time.
* Statistical significance will be set at p\<0.05.
6. Expected Outcomes and Significance

* Primary Outcome: Incidence of DLI in patients with CH-VAD.
* Secondary Outcomes: Risk factors associated with DLI, the impact of DLI on patient outcomes, and the effectiveness of different management strategies.
* The findings from this study could provide valuable insights into the clinical management of CH-VAD patients and inform future advancements in LVAD design to minimize DLI.
7. Timeline

* Study Period: June 2017 to October 2024 (Data collection period).
* Data Analysis Period: November 2024 to January 2025.
* Results Publication: Expected by March 2025.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Driveline Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who received CH-VAD implantations for advanced heart failure between June 2017 and October 2024.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wuhan Asia Heart Hospital

OTHER

Sponsor Role collaborator

Sichuan Provincial People's Hospital

OTHER

Sponsor Role collaborator

Zhejiang Provincial People's Hospital

OTHER

Sponsor Role collaborator

Ruijin Hospital

OTHER

Sponsor Role collaborator

Shanghai Zhongshan Hospital

OTHER

Sponsor Role collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

Sponsor Role collaborator

First Affiliated Hospital Xi'an Jiaotong University

OTHER

Sponsor Role collaborator

China National Center for Cardiovascular Diseases

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Shengshou Hu

Academician of Chinese Academy of Engineering

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fuwai Hospital

Beijing, Beijing Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

Wang X, Zhou X, Chen H, Zhang H, Zhang Y, Cui Y, Huang K, Hua Z, Yan Y, Zhou M, Zhao Q, Sun X, Wang C, Ge Z, Dong A, Hu S. Low driveline infection rates in patients with a novel fully magnetically levitated ventricular assist device. Eur J Cardiothorac Surg. 2025 Oct 25:ezaf365. doi: 10.1093/ejcts/ezaf365. Online ahead of print.

Reference Type DERIVED
PMID: 41137667 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

China-NCCD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Valvular Heart Disease Registry
NCT03488732 RECRUITING